RVD with weekly subcutaneous bortezomib minimizes neuropathy and maintains efficacy in a diverse multiple myeloma cohort

被引：1

作者：

Gill, Amitoj ^{[1
]}

Jayswal, Rani ^{[2
]}

Weiss, Heidi ^{[2
]}

Rhodes, Jill ^{[1
]}

Hegazi, Mohamed ^{[1
]}

Herzig, Geoffrey ^{[1
]}

Herzig, Roger ^{[2
]}

Krem, Maxwell ^{[2
]}

机构：

[1] Univ Louisville, Louisville, KY 40292 USA

[2] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

bortezomib; neuropathy; Tolerability;

D O I：

10.1016/j.clml.2019.09.349

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SP-023

引用

页码：E210 / E210

页数：1

共 50 条

[1] Weekly Dosing of Bortezomib in RVD Achieves Minimal Toxicity with No Reduction in Efficacy in a Diverse Cohort of Multiple Myeloma Patients
Hussaini, Syed
Gill, Amitoj
Gosain, Rahul
Rai, Shesh
Wu, Xiaoyong
Rhodes, Jill
Basu, Soumit K.
Chao, Ju-Hsien
Tse, William
Herzig, Geoffrey P.
Herzig, Roger H.
Krem, Maxwell M.
BLOOD, 2017, 130
[2] Neuropathy and Efficacy Of Weekly Subcutaneous Bortezomib In Myeloma and AL Amyloidosis
Sidana, Surbhi
Faiman, Beth
Elson, Paul
Smith, Mitchell R.
Dean, Robert M.
Valent, Jason
Samaras, Christy
Duong, Hien K.
Hastings, Debbie
Bruening, Kellie
Reu, Frederic J.
BLOOD, 2013, 122 (21)
[3] Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
Sidana, Surbhi
Narkhede, Mayur
Elson, Paul
Hastings, Debbie
Faiman, Beth
Valent, Jason
Samaras, Christy
Hamilton, Kimberly
Liu, Hien K.
Smith, Mitchell R.
Reu, Frederic J.
PLOS ONE, 2017, 12 (03):
[4] Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy
Voorhees, Peter M.
Laubach, Jacob
Anderson, Kenneth C.
Richardson, Paul G.
BLOOD, 2013, 121 (05) : 858 - 858
[5] Subcutaneous Bortezomib In Multiple Myeloma
Hoy, Sheridan M.
DRUGS, 2013, 73 (01) : 45 - 54
[6] Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma
Liu, Hong
Xu, Ruirong
Huang, Hongming
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2016, 12 (05) : 3041 - 3046
[7] Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Bringhen, Sara
Larocca, Alessandra
Rossi, Davide
Cavalli, Maide
Genuardi, Mariella
Ria, Roberto
Gentili, Silvia
Patriarca, Francesca
Nozzoli, Chiara
Levi, Anna
Guglielmelli, Tommasina
Benevolo, Giulia
Callea, Vincenzo
Rizzo, Vincenzo
Cangialosi, Clotilde
Musto, Pellegrino
De Rosa, Luca
Liberati, Anna Marina
Grasso, Mariella
Falcone, Antonietta P.
Evangelista, Andrea
Cavo, Michele
Gaidano, Gianluca
Boccadoro, Mario
Palumbo, Antonio
BLOOD, 2010, 116 (23) : 4745 - 4753
[8] Efficacy and Safety of Once Weekly Bortezomib In Multiple Myeloma Patients.
Bringhen, Sara
Larocca, Alessandra
Rossi, Davide
Romano, Alessandra
Genuardi, Mariella
Ria, Roberto
Leoni, Pietro
Patriarca, Francesca
Nozzoli, Chiara
Guglielmelli, Tommasina
Benevolo, Giulia
Callea, Vincenzo
Gentilini, Fabiana
Elice, Francesca
Olivero, Barbara
Grasso, Mariella
Falcone, Antonietta Pia
Gottardi, Daniela
Montefusco, Vittorio
Allegra, Alessandro
Rizzo, Manuela
Leonardi, Giovanna
Oddolo, Daniela
Morabito, Fortunato
Boccadoro, Mario
Palumbo, Antonio
BLOOD, 2010, 116 (21) : 1248 - 1249
[9] Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
Ashrafi, Farzaneh
Moghaddas, Azadeh
Darakhshandeh, Ali
JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2020, 9 (01) : 56 - 59
[10] Efficacy and safety of bortezomib in once weekly vs. twice weekly dosing in the treatment of multiple myeloma
Ang, Kwan-Keat
Beechinor, Ryan
Quan, Michelle
Tuscano, Joseph
Rosenberg, Aaron
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S152 - S152

← 1 2 3 4 5 →